Cytokinetics (CYTK)
(Delayed Data from NSDQ)
$62.10 USD
-1.92 (-3.00%)
Updated May 10, 2024 04:00 PM ET
After-Market: $62.00 -0.10 (-0.16%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
Cytokinetics, Incorporated [CYTK]
Reports for Purchase
Showing records 21 - 40 ( 305 total )
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Omecamtiv CRL No Surprise and Priced In; No Spend As Wait and See for Partner; Primary Focus on Aficamten
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Cytokinetics Now; Omecamtiv Appears To Have Been Clearing Event for Investors; Target Upped to $56
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Omecamtiv Takes It On the Chin; Playing It Safe and Removing From Valuation; Target Reduced to $29
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Briefing Docs Contain No Real Surprises; Looking Forward to Vibrant Discussion on Tuesday
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
KOL Provides Upbeat Perspective Ahead of Omecamtiv AdCom Meeting
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Clinical Pipeline Expands With an Additional Phase 1 Study of CK-136 in HF
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Taking the Pulse Ahead of Omecamtiv Mecarbil AdCom
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Taking the Pulse Ahead of Omecamtiv Mecarbil AdCom
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Omecamtiv Filing Accepted in China as Excitment Brews Here for AdCom; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
New Data Demonstrate Omecamtiv''s Economic and Clinical Benefit For Men and Women Alike
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
3Q22 Results; Quite Busy Ahead of Critical AdCom; We Look Toward Positive Outcome
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Parallel REDWOOD-HCM OLE Updates Echo Aficamten''s Promise in HCM
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
2Q22 Results; AdCom and PDUFA Dates on the Horizon; Things Getting Real Exciting
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Omecamtiv''s PDUFA Extended on PK Data Fine-Tuning; Our Thesis Remains Unaltered
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Echo Measures Showcase Early Benefits of Aficamten on Cardiac Structure and Function at ASE
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Longer-Term Aficamten Data at ESC-HF Do Not Disappoint; Omecamtiv Continues to Strengthen Its Profile
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
1Q22 Results; Late Stage Execution Continues According to Plan
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Mavacamten Crosses the Finish Line; We are Confident Aficamten Is Next and Could Do Better; Target Increased to $75
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Cardiac Myosin Inhibitors Shine at ACC.22; Full REDWOOD-HCM Cohort 3 Results Impress
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
2021 Results; Late Stage Execution Continues With Solid Strategy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J